Novavax Global Commercial Operations and COVID-19 Vaccine Update

Study 307: Demographics and baseline characteristics Lot 1 (N = 298) Lot 2 (N = 303) Age (years) - median (range) 37.0 (19 - 49) 38.0 (18-49) Female 58.7% 54.5% Race Lot 3 (N = 304) 38.0 (18 - 49) 61.2% White 73.5% 73.6% 75.0% Black or African American 18.1% 20.1% 16.8% Asian 3.7% 3.3% 3.0% Median interval to boost (Days) 266 269 262 Previous vaccine Pfizer x 2 23.5% 24.1% 19.7% Previous vaccine Pfizer x 3 26.5% 29.4% 33.9% Previous vaccine Moderna x 2 16.4% 14.9% 17.1% Previous vaccine Moderna x 3 17.1% 15.2% 14.1% PCR positive at Baseline. 2.3% 2.6% 2.0% novavax © 2023 NOVAVAX. All rights reserved. 46

View entire presentation